Creo Medical Group (LON:CREO) Earns “House Stock” Rating from Shore Capital Group

Creo Medical Group (LON:CREO)‘s stock had its “house stock” rating restated by equities researchers at Shore Capital Group in a report released on Thursday, Marketbeat.com reports. They presently have a GBX 40 price objective on the stock. Shore Capital Group’s price target indicates a potential upside of 190.91% from the company’s previous close.

Creo Medical Group Price Performance

Creo Medical Group stock opened at GBX 13.75 on Thursday. Creo Medical Group has a 12 month low of GBX 9.52 and a 12 month high of GBX 18.50. The company has a debt-to-equity ratio of 8.20, a current ratio of 3.22 and a quick ratio of 2.19. The business has a 50 day simple moving average of GBX 13.74 and a 200-day simple moving average of GBX 13.30. The stock has a market capitalization of £66.80 million, a PE ratio of 13.75 and a beta of 1.62.

Creo Medical Group (LON:CREO) last posted its quarterly earnings data on Friday, May 22nd. The company reported GBX (0.04) earnings per share for the quarter. The firm had revenue of GBX 600 million during the quarter. Creo Medical Group had a net margin of 88.33% and a return on equity of 9.56%. Equities analysts predict that Creo Medical Group will post -10.0800005 earnings per share for the current year.

Insider Activity

In other news, insider Craig Jonathan Gulliford purchased 6,250 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were acquired at an average cost of GBX 14 per share, for a total transaction of £875. Also, insider Richard John Rees acquired 6,250 shares of Creo Medical Group stock in a transaction that occurred on Wednesday, July 1st. The stock was purchased at an average price of GBX 14 per share, with a total value of £875. 6.92% of the stock is owned by insiders.

Creo Medical Group Company Profile

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.